NCT07444489 · Interventional trial
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Overall registry status Enrolling by invitation
Phase 3
Conditions Antibody-mediated Rejection, Microvascular Inflammation
Delaware Valley sites
- Penn Medicine - Hospital of the University of Pennsylvania · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory